JP4057091B2 - 細菌株、及び該細菌株を含む薬学的組成物、並びに胆汁酸に関しての変化した代謝に関連するか、引き起こされる疾患を治療するための、上記組成物の使用 - Google Patents

細菌株、及び該細菌株を含む薬学的組成物、並びに胆汁酸に関しての変化した代謝に関連するか、引き起こされる疾患を治療するための、上記組成物の使用 Download PDF

Info

Publication number
JP4057091B2
JP4057091B2 JP05367397A JP5367397A JP4057091B2 JP 4057091 B2 JP4057091 B2 JP 4057091B2 JP 05367397 A JP05367397 A JP 05367397A JP 5367397 A JP5367397 A JP 5367397A JP 4057091 B2 JP4057091 B2 JP 4057091B2
Authority
JP
Japan
Prior art keywords
cultures
microorganismes
bile
strains
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP05367397A
Other languages
English (en)
Japanese (ja)
Other versions
JPH1086A (ja
Inventor
レナータ・マリア・アンナ・カバリエレ・ベセリー
クラウディオ・デ・シモーネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RENATA MARIA ANNA CAVALIERE VESELY
Original Assignee
RENATA MARIA ANNA CAVALIERE VESELY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11373572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4057091(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by RENATA MARIA ANNA CAVALIERE VESELY filed Critical RENATA MARIA ANNA CAVALIERE VESELY
Publication of JPH1086A publication Critical patent/JPH1086A/ja
Application granted granted Critical
Publication of JP4057091B2 publication Critical patent/JP4057091B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP05367397A 1996-03-11 1997-03-07 細菌株、及び該細菌株を含む薬学的組成物、並びに胆汁酸に関しての変化した代謝に関連するか、引き起こされる疾患を治療するための、上記組成物の使用 Expired - Lifetime JP4057091B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96MI000468A IT1283225B1 (it) 1996-03-11 1996-03-11 Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
IT96A000468 1996-03-11

Publications (2)

Publication Number Publication Date
JPH1086A JPH1086A (ja) 1998-01-06
JP4057091B2 true JP4057091B2 (ja) 2008-03-05

Family

ID=11373572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP05367397A Expired - Lifetime JP4057091B2 (ja) 1996-03-11 1997-03-07 細菌株、及び該細菌株を含む薬学的組成物、並びに胆汁酸に関しての変化した代謝に関連するか、引き起こされる疾患を治療するための、上記組成物の使用

Country Status (13)

Country Link
US (6) US6225104B1 (enExample)
EP (1) EP0795604B1 (enExample)
JP (1) JP4057091B2 (enExample)
KR (1) KR100472061B1 (enExample)
CN (1) CN1110547C (enExample)
AT (1) ATE246509T1 (enExample)
CA (1) CA2198518C (enExample)
DE (1) DE69723898T2 (enExample)
DK (1) DK0795604T3 (enExample)
ES (1) ES2200145T3 (enExample)
IT (1) IT1283225B1 (enExample)
MX (1) MX9701816A (enExample)
PT (1) PT795604E (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
IT1309427B1 (it) * 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
IT1306716B1 (it) * 1999-06-21 2001-10-02 Mendes S U R L Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
ITRM20010763A1 (it) * 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
US7374606B2 (en) * 2003-06-27 2008-05-20 Canon Kabushiki Kaisha Water-based ink and ink recording method
US7985564B2 (en) * 2003-11-21 2011-07-26 Pfenex, Inc. Expression systems with sec-system secretion
CN1663573B (zh) * 2004-03-04 2010-04-28 青岛东海药业有限公司 一种稳定安全的微生态制剂及其制备方法和用途
WO2005094848A1 (ja) * 2004-03-31 2005-10-13 Calpis Co., Ltd. 肝障害予防又は抑制剤及び肝障害予防又は抑制用機能性食品
EP2468869B1 (en) * 2007-01-31 2015-03-18 Pfenex Inc. Bacterial leader sequences for increased expression
PL2266619T3 (pl) * 2008-03-04 2015-10-30 Dikovskiy Aleksander Vladimirovich Kompozycja farmaceutyczna na bazie środków chroniących wątrobę i środków prebiotycznych, ich wytwarzanie i zastosowanie
KR20220042485A (ko) * 2012-01-16 2022-04-05 엘라자베스 맥켄나 간 질환들 및 장애들의 치료를 위한 조성물들 및 방법들
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
EP2898073A4 (en) 2012-09-21 2016-03-23 Elizabeth Mckenna Naturally-occurring CPG-oligonucleotide compositions and therapeutic applications thereof
EP3172973B1 (en) * 2015-11-27 2020-04-08 DAFLORN Ltd. Probiotic formula, process of its preparation and use
BR112018012022A2 (pt) * 2015-12-14 2018-12-04 Metabogen Ab ?composição, e, método para tratamento ou redução do risco de colestase intra-hepática?
CN115569141B (zh) * 2022-10-17 2023-10-20 中国农业科学院兰州兽医研究所 脱氧胆酸在制备抗口腔链球菌产品中的应用
WO2025094993A1 (ja) * 2023-10-31 2025-05-08 国立大学法人大阪大学 Ｍａｉｔ細胞リガンドの同定のための細胞、および当該細胞を用いるｍａｉｔ細胞リガンドのスクリーニング方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1221734B (it) * 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US5079240A (en) * 1990-03-15 1992-01-07 The Regents Of The University Of California Synthetic conjugated bile acid and method of use thereof
US5716615A (en) * 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
IT1255241B (it) * 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia
JP2992945B2 (ja) * 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
DE69600525T2 (de) * 1996-12-23 1998-12-10 Sitia-Yomo S.P.A., Mailand/Milano Lyophilisierte, lebende Bakerien enthaltende Nahrungszusammensetzung
IT1309427B1 (it) * 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
ITRM20010763A1 (it) * 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
TWI241912B (en) * 2002-10-30 2005-10-21 Food Industry Res & Dev Inst Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol

Also Published As

Publication number Publication date
ITMI960468A1 (it) 1997-09-11
DK0795604T3 (da) 2003-10-27
EP0795604B1 (en) 2003-08-06
ITMI960468A0 (enExample) 1996-03-11
US20030082791A1 (en) 2003-05-01
US6225104B1 (en) 2001-05-01
JPH1086A (ja) 1998-01-06
CN1165857A (zh) 1997-11-26
PT795604E (pt) 2003-12-31
ATE246509T1 (de) 2003-08-15
US20110217759A1 (en) 2011-09-08
KR100472061B1 (ko) 2005-07-08
DE69723898D1 (de) 2003-09-11
CA2198518C (en) 2010-04-13
MX9701816A (es) 1998-04-30
US20040259227A1 (en) 2004-12-23
US20010012629A1 (en) 2001-08-09
CN1110547C (zh) 2003-06-04
US7959911B2 (en) 2011-06-14
USRE41276E1 (en) 2010-04-27
CA2198518A1 (en) 1997-09-11
IT1283225B1 (it) 1998-04-16
DE69723898T2 (de) 2004-01-29
KR970065708A (ko) 1997-10-13
EP0795604A2 (en) 1997-09-17
ES2200145T3 (es) 2004-03-01
EP0795604A3 (en) 1998-04-15

Similar Documents

Publication Publication Date Title
JP4057091B2 (ja) 細菌株、及び該細菌株を含む薬学的組成物、並びに胆汁酸に関しての変化した代謝に関連するか、引き起こされる疾患を治療するための、上記組成物の使用
Thomas et al. Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis
Bartram et al. Does yogurt enriched with Bifidobacterium longum affect colonic microbiology and fecal metabolites in healthy subjects?
Gallaher et al. Probiotics, Cecal Microflora, and Aberrant Crypts in the Rat Colon1, 2
Hill The role of colon anaerobes in the metabolism of bile acids and steroids, and its relation to colon cancer
Mastromarino et al. Metabolic epidemiology of colon cancer: enzymic activity of fecal flora
Dickinson et al. Determination of bile acid conversion potencies of intestinal bacteria by screening in vitro and subsequent establishment in germfree rats
Li et al. Effect of feeding of a cholesterol-reducing bacterium, Eubacterium coprostanoligenes, to germ-free mice
KR100934747B1 (ko) 새로운 젖산균 균주, 이를 함유하는 식용 조성물, 약물 및수의학적 제품
MXPA97001816A (en) Bacterials and pharmaceutical composition containing such strains and using the same to prevent and treat diseases associated with metabolism altered biliary deactives or caused by my
EP0555618A2 (en) Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
JPS60149527A (ja) 生体内脱臭剤
DE60002194T3 (de) Zusammensetzung enthaltend alkalische sphingomyelase von bakteriellem ursprung zum gebrauch als diätetische zusammensetzung, nahrungsergänzungsmittel oder pharmazeutisches produkt
EP2266619B1 (de) Pharmazeutische zusammensetzung auf basis eines leberschützenden mittels und eines präbiotischen mittels, ihre herstellung und verwendung
Yanahira et al. Effects of lactitol-oligosaccharides on the intestinal microflora in rats
Prabha et al. Bacterial transformations of bile acids
Gorbach The intestinal microflora and its colon cancer connection
KR20230088249A (ko) 생체 직교성 클릭 화학을 통한 외재성 프로바이오틱스의 장내 집락화용 조성물 및 키트
Hashimoto et al. Effects of β-lactam antibiotics on intestinal microflora and bile acid metabolism in rats
Midtvedt et al. Adsorption of bile acids to intestinal microorganisms
CN117625588A (zh) 一种治疗非酒精性脂肪肝的活菌复合物
Sauer et al. In patients with orthotopic liver transplantation, serum markers of cholestasis are unreliable indicators of biliary secretion
ROY et al. Clinical implications of bile acids in paediatrics
US20230201360A1 (en) Composition and Kit for colonization in gut of external probiotics through bioorthogonal click chemistry
JP4572185B2 (ja) 酪酸菌及び／又は乳酸菌を含有してなる消化管洗浄助剤

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070703

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071213

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101221

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111221

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111221

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121221

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131221

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term